Remedent, Inc.
REMI · OTC
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $1 | $2 | $3 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $2 | $3 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -23% | 78.1% | -14.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 63.6% | 65.7% | 58.2% | 54% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -80.5% | 17.6% | -16.3% | -16.7% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -86.4% | 10.9% | -15.9% | -28.4% |
| EPS Diluted | -0.011 | 0.002 | -0.002 | -0.003 |
| % Growth | -711.1% | 220% | 51.6% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |